Cargando…
DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast.
The relationship between DNA content of mammary cancer and subsequent response to endocrine therapy was studied in 136 patients with advanced disease. All were treated with tamoxifen or ovarian ablation as first-line systemic therapy after relapse and were evaluable for response according to UICC cr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001728/ https://www.ncbi.nlm.nih.gov/pubmed/3038158 |
_version_ | 1782135663716466688 |
---|---|
author | Baildam, A. D. Zaloudik, J. Howell, A. Barnes, D. M. Turnbull, L. Swindell, R. Moore, M. Sellwood, R. A. |
author_facet | Baildam, A. D. Zaloudik, J. Howell, A. Barnes, D. M. Turnbull, L. Swindell, R. Moore, M. Sellwood, R. A. |
author_sort | Baildam, A. D. |
collection | PubMed |
description | The relationship between DNA content of mammary cancer and subsequent response to endocrine therapy was studied in 136 patients with advanced disease. All were treated with tamoxifen or ovarian ablation as first-line systemic therapy after relapse and were evaluable for response according to UICC criteria. DNA characterisation by flow cytometry was used on formalin fixed paraffin-embedded samples of tumour. Tumours were grouped according to DNA index into diploid (n = 52, 38%), 'tetraploid' (n = 46, 34%) and 'other DNA-aneuploid' (n = 38, 28%). The highest proportion of oestrogen receptor positive tumours (ER + ve) was found in the 'tetraploid' tumours (38/46, 85%, Chi-square = 8.53, P less than 0.02), and response rates, (SD + PR + CR), were 26/52 (50%), 34/46 (74%), and 15/38 (39%) respectively (Chi-square = 10.88, P less than 0.005). Patients with diploid or 'tetraploid' tumours survived longer and stayed in remission longer than those with 'other DNA-aneuploid' tumours. We suggest that 'tetraploid' or 'near tetraploid' human mammary tumours may comprise a distinct group of endocrine responsive tumours within the overall group of aneuploid tumours. The conventional interpretation of DNA histograms, grouping into diploid and aneuploid, may be masking important features of some tumour groups. |
format | Text |
id | pubmed-2001728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1987 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20017282009-09-10 DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. Baildam, A. D. Zaloudik, J. Howell, A. Barnes, D. M. Turnbull, L. Swindell, R. Moore, M. Sellwood, R. A. Br J Cancer Research Article The relationship between DNA content of mammary cancer and subsequent response to endocrine therapy was studied in 136 patients with advanced disease. All were treated with tamoxifen or ovarian ablation as first-line systemic therapy after relapse and were evaluable for response according to UICC criteria. DNA characterisation by flow cytometry was used on formalin fixed paraffin-embedded samples of tumour. Tumours were grouped according to DNA index into diploid (n = 52, 38%), 'tetraploid' (n = 46, 34%) and 'other DNA-aneuploid' (n = 38, 28%). The highest proportion of oestrogen receptor positive tumours (ER + ve) was found in the 'tetraploid' tumours (38/46, 85%, Chi-square = 8.53, P less than 0.02), and response rates, (SD + PR + CR), were 26/52 (50%), 34/46 (74%), and 15/38 (39%) respectively (Chi-square = 10.88, P less than 0.005). Patients with diploid or 'tetraploid' tumours survived longer and stayed in remission longer than those with 'other DNA-aneuploid' tumours. We suggest that 'tetraploid' or 'near tetraploid' human mammary tumours may comprise a distinct group of endocrine responsive tumours within the overall group of aneuploid tumours. The conventional interpretation of DNA histograms, grouping into diploid and aneuploid, may be masking important features of some tumour groups. Nature Publishing Group 1987-05 /pmc/articles/PMC2001728/ /pubmed/3038158 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Baildam, A. D. Zaloudik, J. Howell, A. Barnes, D. M. Turnbull, L. Swindell, R. Moore, M. Sellwood, R. A. DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. |
title | DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. |
title_full | DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. |
title_fullStr | DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. |
title_full_unstemmed | DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. |
title_short | DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. |
title_sort | dna analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001728/ https://www.ncbi.nlm.nih.gov/pubmed/3038158 |
work_keys_str_mv | AT baildamad dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast AT zaloudikj dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast AT howella dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast AT barnesdm dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast AT turnbulll dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast AT swindellr dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast AT moorem dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast AT sellwoodra dnaanalysisbyflowcytometryresponsetoendocrinetreatmentandprognosisinadvancedcarcinomaofthebreast |